Close Menu

Regulus

The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics.

The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year.

The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.

Regulus said it was able to develop its miRNA extraction and profiling technology to meet the quality specifications set out by its partner.

The delivery approach has gained traction in recent years and is being explored by a number of RNA drug firms.

The data show that RG-012 can enhance the effect of Sanofi's kidney protectant ramipril and suggest the microRNA drug might have use in other chronic kidney diseases.

NEW YORK (GenomeWeb) — October was a turbulent month on Wall Street for several key RNAi/microRNA players, with two companies — Regulus Therapeutics and Alnylam Pharmaceuticals — seeing major gains on encouraging clinical data and two others — Arrowhead Research and Tekmira Pharmaceuticals — taki

NEW YORK (GenomeWeb) — Buoyed by positive Phase I data on its microRNA-targeting hepatitis C drug RG-101, Regulus Therapeutics is aiming to begin Phase II testing of the dr

NEW YORK (GenomeWeb) — Regulus Therapeutics announced this week that it has closed its previously announced public stock offering, raising $103.5 million through the transaction.

NEW YORK (GenomeWeb) — Regulus Therapeutics this week announced that it had priced its previously announced public offering of roughly 5.3 million shares of its common stock at $17 apiece, valuing the transaction at about $90 million.

Pages

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.